Healthcare provider profile · identity verified

David William Jahn, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · TOLEDO, OH · NPI 1508802224

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show David William Jahn, MD received $125,002.99 in general payments during 2025 across 273 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 39.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 24 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Auvelity, Caplyta, Ingrezza, Invega Sustenna, Lybalvi, Rexulti, Trintellix, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viibryd by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Aristada by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Lybalvi by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Auvelity by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Invega Sustenna by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Abilify Maintena by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rexulti by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ingrezza by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Abilify Maintena by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trintellix by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$125,002.99

273 reported records · 18 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$49,322.60	39.5%	65	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$20,125.82	16.1%	38	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$19,007.05	15.2%	37	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$17,888.00	14.3%	23	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$16,900.44	13.5%	27	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$411.08	0.3%	13	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$318.62	0.2%	17	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$266.59	0.2%	11	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$194.52	0.2%	12	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$146.71	0.1%	9	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$109.45	0.1%	5	2025
Corium, LLC	Unresolved — no canonical attribution shown	$91.79	0.1%	5	2025
Bausch Health US, LLC	Unresolved — no canonical attribution shown	$63.91	0.1%	3	2025
Luye Pharma (USA) Ltd.	Unresolved — no canonical attribution shown	$48.33	0.0%	2	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$36.91	0.0%	2	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$32.42	0.0%	2	2025
Sage Therapeutics, LLC	Unresolved — no canonical attribution shown	$20.50	0.0%	1	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$18.25	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$92,530.00	35
Honoraria	$14,982.50	5
Travel and Lodging	$7,348.74	44
Food and Beverage	$6,621.75	188
Consulting Fee	$3,520.00	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$49,322.60	65	2025
Source payment records 2025-01-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.36 · Open Payments source 2025-01-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.06 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.83 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,360.00 · Open Payments source 2025-04-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $203.00 · Open Payments source 2025-05-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.90 · Open Payments source 2025-06-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.32 · Open Payments source 2025-07-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.93 · Open Payments source 2025-07-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.03 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $219.80 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.31 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.18 · Open Payments source 2025-09-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.53 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.31 · Open Payments source 2025-09-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.23 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $371.97 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.70 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $235.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $306.75 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.87 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.33 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.57 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $104.36 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.23 · Open Payments source 2025-10-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.31 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $113.40 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.04 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $84.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $88.00 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $115.17 · Open Payments source 2025-11-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.81 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $142.80 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $93.80 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.79 · Open Payments source 2025-11-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.62 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.01 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $94.87 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.94 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $121.51 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $182.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $197.40 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $183.40 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.22 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $91.00 · Open Payments source 2025-12-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.25 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.74 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $177.28 · Open Payments source 2025-12-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.55 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $75.60 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,760.00 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$20,125.82	38	2025
Source payment records 2025-04-25 · Vanda Pharmaceuticals Inc. · $14.55 · Open Payments source 2025-05-16 · Vanda Pharmaceuticals Inc. · $7.75 · Open Payments source 2025-06-10 · Vanda Pharmaceuticals Inc. · $17.87 · Open Payments source 2025-07-18 · Vanda Pharmaceuticals Inc. · $17.59 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $178.12 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $4,455.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $480.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $532.96 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $86.80 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $88.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $438.44 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $2.66 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $79.73 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $3.99 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $29.52 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $69.90 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $32.61 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $49.55 · Open Payments source 2025-08-22 · Vanda Pharmaceuticals Inc. · $11.98 · Open Payments source 2025-09-04 · Vanda Pharmaceuticals Inc. · $9.50 · Open Payments source 2025-09-19 · Vanda Pharmaceuticals Inc. · $29.15 · Open Payments source 2025-10-07 · Vanda Pharmaceuticals Inc. · $107.68 · Open Payments source 2025-10-07 · Vanda Pharmaceuticals Inc. · $2,475.00 · Open Payments source 2025-10-07 · Vanda Pharmaceuticals Inc. · $214.20 · Open Payments source 2025-10-08 · Vanda Pharmaceuticals Inc. · $124.74 · Open Payments source 2025-10-08 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-10-08 · Vanda Pharmaceuticals Inc. · $91.00 · Open Payments source 2025-10-14 · Vanda Pharmaceuticals Inc. · $30.79 · Open Payments source 2025-10-22 · Vanda Pharmaceuticals Inc. · $35.00 · Open Payments source 2025-10-22 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-10-22 · Vanda Pharmaceuticals Inc. · $74.76 · Open Payments source 2025-10-29 · Vanda Pharmaceuticals Inc. · $112.35 · Open Payments source 2025-10-29 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-11-13 · Vanda Pharmaceuticals Inc. · $35.27 · Open Payments source 2025-12-03 · Vanda Pharmaceuticals Inc. · $9.26 · Open Payments source 2025-12-03 · Vanda Pharmaceuticals Inc. · $2,145.00 · Open Payments source 2025-12-03 · Vanda Pharmaceuticals Inc. · $280.10 · Open Payments source 2025-12-03 · Vanda Pharmaceuticals Inc. · $2,145.00 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$19,007.05	37	2025
Source payment records 2025-01-07 · ABBVIE INC. · $11.19 · Open Payments source 2025-01-15 · ABBVIE INC. · $22.33 · Open Payments source 2025-04-07 · ABBVIE INC. · $525.00 · Open Payments source 2025-05-15 · ABBVIE INC. · $7.92 · Open Payments source 2025-05-30 · ABBVIE INC. · $14.10 · Open Payments source 2025-06-17 · ABBVIE INC. · $4.31 · Open Payments source 2025-06-18 · ABBVIE INC. · $69.39 · Open Payments source 2025-06-18 · ABBVIE INC. · $15.62 · Open Payments source 2025-06-18 · ABBVIE INC. · $34.30 · Open Payments source 2025-06-18 · ABBVIE INC. · $1.25 · Open Payments source 2025-06-18 · ABBVIE INC. · $69.30 · Open Payments source 2025-06-18 · ABBVIE INC. · $3.25 · Open Payments source 2025-06-20 · ABBVIE INC. · $122.11 · Open Payments source 2025-06-24 · ABBVIE INC. · $19.80 · Open Payments source 2025-06-28 · ABBVIE INC. · $9.32 · Open Payments source 2025-07-02 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-07-02 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-07-02 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-07-22 · ABBVIE INC. · $14.22 · Open Payments source 2025-08-08 · ABBVIE INC. · $14.66 · Open Payments source 2025-08-20 · ABBVIE INC. · $3,150.00 · Open Payments source 2025-08-20 · ABBVIE INC. · $110.60 · Open Payments source 2025-08-29 · ABBVIE INC. · $23.24 · Open Payments source 2025-09-03 · ABBVIE INC. · $13.20 · Open Payments source 2025-09-24 · ABBVIE INC. · $110.60 · Open Payments source 2025-09-24 · ABBVIE INC. · $6.50 · Open Payments source 2025-09-24 · ABBVIE INC. · $3,150.00 · Open Payments source 2025-09-24 · ABBVIE INC. · $16.05 · Open Payments source 2025-10-02 · ABBVIE INC. · $15.41 · Open Payments source 2025-10-23 · ABBVIE INC. · $125.01 · Open Payments source 2025-11-06 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-11-12 · ABBVIE INC. · $15.15 · Open Payments source 2025-11-26 · ABBVIE INC. · $11.28 · Open Payments source 2025-12-05 · ABBVIE INC. · $25.19 · Open Payments source 2025-12-10 · ABBVIE INC. · $13.00 · Open Payments source 2025-12-22 · ABBVIE INC. · $13.75 · Open Payments source 2025-12-23 · ABBVIE INC. · $2,250.00 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$17,825.62	20	2025
Source payment records 2025-04-09 · Janssen Pharmaceuticals, Inc · $120.65 · Open Payments source 2025-04-12 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-04-16 · Janssen Pharmaceuticals, Inc · $170.80 · Open Payments source 2025-05-29 · Janssen Pharmaceuticals, Inc · $26.50 · Open Payments source 2025-07-08 · Janssen Pharmaceuticals, Inc · $147.40 · Open Payments source 2025-07-12 · Janssen Pharmaceuticals, Inc · $450.00 · Open Payments source 2025-07-15 · Janssen Pharmaceuticals, Inc · $67.20 · Open Payments source 2025-07-15 · Janssen Pharmaceuticals, Inc · $2,700.00 · Open Payments source 2025-08-13 · Janssen Pharmaceuticals, Inc · $117.54 · Open Payments source 2025-08-18 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-08-18 · Janssen Pharmaceuticals, Inc · $127.40 · Open Payments source 2025-09-15 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-09-17 · Janssen Pharmaceuticals, Inc · $257.60 · Open Payments source 2025-09-18 · Janssen Pharmaceuticals, Inc · $118.72 · Open Payments source 2025-09-22 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $169.40 · Open Payments source 2025-10-16 · Janssen Pharmaceuticals, Inc · $26.10 · Open Payments source 2025-10-27 · Janssen Pharmaceuticals, Inc · $20.77 · Open Payments source 2025-11-17 · Janssen Pharmaceuticals, Inc · $30.54 · Open Payments source 2025-12-17 · Janssen Pharmaceuticals, Inc · $675.00 · Open Payments source
INVEGA TRINZA Normalized: invega trinza	Drug	Janssen Pharmaceuticals, Inc	$17,334.94	13	2025
Source payment records 2025-04-12 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-04-16 · Janssen Pharmaceuticals, Inc · $170.80 · Open Payments source 2025-07-12 · Janssen Pharmaceuticals, Inc · $450.00 · Open Payments source 2025-07-15 · Janssen Pharmaceuticals, Inc · $67.20 · Open Payments source 2025-07-15 · Janssen Pharmaceuticals, Inc · $2,700.00 · Open Payments source 2025-08-13 · Janssen Pharmaceuticals, Inc · $117.54 · Open Payments source 2025-08-18 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-08-18 · Janssen Pharmaceuticals, Inc · $127.40 · Open Payments source 2025-09-15 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-09-17 · Janssen Pharmaceuticals, Inc · $257.60 · Open Payments source 2025-09-22 · Janssen Pharmaceuticals, Inc · $3,150.00 · Open Payments source 2025-09-24 · Janssen Pharmaceuticals, Inc · $169.40 · Open Payments source 2025-12-17 · Janssen Pharmaceuticals, Inc · $675.00 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$16,900.44	27	2025
Source payment records 2025-03-15 · Axsome Therapeutics, Inc. · $29.45 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $125.13 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $48.79 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $26.77 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $60.36 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $45.30 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $32.93 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $78.04 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $553.97 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $234.83 · Open Payments source 2025-04-03 · Axsome Therapeutics, Inc. · $7,225.00 · Open Payments source 2025-04-09 · Axsome Therapeutics, Inc. · $75.60 · Open Payments source 2025-04-15 · Axsome Therapeutics, Inc. · $30.33 · Open Payments source 2025-04-30 · Axsome Therapeutics, Inc. · $1,913.00 · Open Payments source 2025-04-30 · Axsome Therapeutics, Inc. · $125.00 · Open Payments source 2025-04-30 · Axsome Therapeutics, Inc. · $19.60 · Open Payments source 2025-05-05 · Axsome Therapeutics, Inc. · $21.45 · Open Payments source 2025-05-07 · Axsome Therapeutics, Inc. · $956.50 · Open Payments source 2025-05-14 · Axsome Therapeutics, Inc. · $2,763.00 · Open Payments source 2025-05-14 · Axsome Therapeutics, Inc. · $123.58 · Open Payments source 2025-05-14 · Axsome Therapeutics, Inc. · $127.40 · Open Payments source 2025-07-28 · Axsome Therapeutics, Inc. · $12.06 · Open Payments source 2025-08-05 · Axsome Therapeutics, Inc. · $23.16 · Open Payments source 2025-10-06 · Axsome Therapeutics, Inc. · $24.03 · Open Payments source 2025-11-24 · Axsome Therapeutics, Inc. · $8.18 · Open Payments source 2025-11-26 · Axsome Therapeutics, Inc. · $2,125.00 · Open Payments source 2025-11-26 · Axsome Therapeutics, Inc. · $91.98 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$318.62	17	2025
Source payment records 2025-01-02 · Neurocrine BioSciences, Inc. · $20.91 · Open Payments source 2025-01-17 · Neurocrine BioSciences, Inc. · $6.96 · Open Payments source 2025-01-24 · Neurocrine BioSciences, Inc. · $4.71 · Open Payments source 2025-04-22 · Neurocrine BioSciences, Inc. · $28.00 · Open Payments source 2025-05-01 · Neurocrine BioSciences, Inc. · $65.46 · Open Payments source 2025-05-09 · Neurocrine BioSciences, Inc. · $28.59 · Open Payments source 2025-06-03 · Neurocrine BioSciences, Inc. · $5.35 · Open Payments source 2025-06-13 · Neurocrine BioSciences, Inc. · $24.96 · Open Payments source 2025-06-16 · Neurocrine BioSciences, Inc. · $5.37 · Open Payments source 2025-06-30 · Neurocrine BioSciences, Inc. · $13.59 · Open Payments source 2025-07-10 · Neurocrine BioSciences, Inc. · $5.50 · Open Payments source 2025-08-11 · Neurocrine BioSciences, Inc. · $7.18 · Open Payments source 2025-08-12 · Neurocrine BioSciences, Inc. · $27.12 · Open Payments source 2025-09-05 · Neurocrine BioSciences, Inc. · $23.09 · Open Payments source 2025-10-17 · Neurocrine BioSciences, Inc. · $5.40 · Open Payments source 2025-12-01 · Neurocrine BioSciences, Inc. · $26.70 · Open Payments source 2025-12-18 · Neurocrine BioSciences, Inc. · $19.73 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$298.35	12	2025
Source payment records 2025-01-10 · Otsuka America Pharmaceutical, Inc. · $17.35 · Open Payments source 2025-04-15 · Otsuka America Pharmaceutical, Inc. · $4.72 · Open Payments source 2025-05-15 · Otsuka America Pharmaceutical, Inc. · $13.31 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $109.61 · Open Payments source 2025-06-12 · Otsuka America Pharmaceutical, Inc. · $17.59 · Open Payments source 2025-06-27 · Lundbeck LLC · $27.73 · Open Payments source 2025-07-15 · Lundbeck LLC · $22.99 · Open Payments source 2025-08-14 · Lundbeck LLC · $23.40 · Open Payments source 2025-09-18 · Otsuka America Pharmaceutical, Inc. · $17.98 · Open Payments source 2025-09-25 · Lundbeck LLC · $16.87 · Open Payments source 2025-09-30 · Otsuka America Pharmaceutical, Inc. · $8.34 · Open Payments source 2025-10-09 · Lundbeck LLC · $18.46 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$260.97	9	2025
Source payment records 2025-01-16 · Teva Pharmaceuticals USA, Inc. · $17.06 · Open Payments source 2025-05-13 · Teva Pharmaceuticals USA, Inc. · $12.93 · Open Payments source 2025-06-19 · Teva Pharmaceuticals USA, Inc. · $14.55 · Open Payments source 2025-07-07 · Teva Pharmaceuticals USA, Inc. · $19.17 · Open Payments source 2025-08-07 · Teva Pharmaceuticals USA, Inc. · $111.25 · Open Payments source 2025-08-21 · Teva Pharmaceuticals USA, Inc. · $21.63 · Open Payments source 2025-10-03 · Teva Pharmaceuticals USA, Inc. · $23.12 · Open Payments source 2025-12-15 · Teva Pharmaceuticals USA, Inc. · $20.63 · Open Payments source 2025-12-15 · Teva Pharmaceuticals USA, Inc. · $20.63 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$194.52	12	2025
Source payment records 2025-01-30 · E.R. Squibb & Sons, L.L.C. · $19.61 · Open Payments source 2025-04-29 · E.R. Squibb & Sons, L.L.C. · $8.30 · Open Payments source 2025-05-23 · E.R. Squibb & Sons, L.L.C. · $15.04 · Open Payments source 2025-06-20 · E.R. Squibb & Sons, L.L.C. · $17.80 · Open Payments source 2025-07-31 · E.R. Squibb & Sons, L.L.C. · $18.05 · Open Payments source 2025-08-19 · E.R. Squibb & Sons, L.L.C. · $15.74 · Open Payments source 2025-08-28 · E.R. Squibb & Sons, L.L.C. · $17.62 · Open Payments source 2025-09-11 · E.R. Squibb & Sons, L.L.C. · $18.48 · Open Payments source 2025-09-23 · E.R. Squibb & Sons, L.L.C. · $14.32 · Open Payments source 2025-10-16 · E.R. Squibb & Sons, L.L.C. · $14.40 · Open Payments source 2025-10-23 · E.R. Squibb & Sons, L.L.C. · $14.99 · Open Payments source 2025-11-11 · E.R. Squibb & Sons, L.L.C. · $20.17 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$150.11	4	2025
Source payment records 2025-04-24 · Teva Pharmaceuticals USA, Inc. · $14.24 · Open Payments source 2025-04-29 · Teva Pharmaceuticals USA, Inc. · $125.00 · Open Payments source 2025-09-15 · Teva Pharmaceuticals USA, Inc. · $7.54 · Open Payments source 2025-09-24 · Teva Pharmaceuticals USA, Inc. · $3.33 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$146.71	9	2025
Source payment records 2025-04-17 · Alkermes, Inc. · $20.65 · Open Payments source 2025-05-08 · Alkermes, Inc. · $19.76 · Open Payments source 2025-06-20 · Alkermes, Inc. · $13.14 · Open Payments source 2025-07-04 · Alkermes, Inc. · $18.31 · Open Payments source 2025-07-17 · Alkermes, Inc. · $18.07 · Open Payments source 2025-09-04 · Alkermes, Inc. · $12.25 · Open Payments source 2025-09-16 · Alkermes, Inc. · $14.16 · Open Payments source 2025-10-30 · Alkermes, Inc. · $12.57 · Open Payments source 2025-12-02 · Alkermes, Inc. · $17.80 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$146.71	9	2025
Source payment records 2025-04-17 · Alkermes, Inc. · $20.65 · Open Payments source 2025-05-08 · Alkermes, Inc. · $19.76 · Open Payments source 2025-06-20 · Alkermes, Inc. · $13.14 · Open Payments source 2025-07-04 · Alkermes, Inc. · $18.31 · Open Payments source 2025-07-17 · Alkermes, Inc. · $18.07 · Open Payments source 2025-09-04 · Alkermes, Inc. · $12.25 · Open Payments source 2025-09-16 · Alkermes, Inc. · $14.16 · Open Payments source 2025-10-30 · Alkermes, Inc. · $12.57 · Open Payments source 2025-12-02 · Alkermes, Inc. · $17.80 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$91.79	5	2025
Source payment records 2025-06-23 · Corium, LLC · $22.56 · Open Payments source 2025-07-17 · Corium, LLC · $8.95 · Open Payments source 2025-08-26 · Corium, LLC · $22.89 · Open Payments source 2025-09-30 · Corium, LLC · $21.06 · Open Payments source 2025-10-28 · Corium, LLC · $16.33 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$77.69	4	2025
Source payment records 2025-01-23 · Otsuka America Pharmaceutical, Inc. · $14.31 · Open Payments source 2025-06-02 · Otsuka America Pharmaceutical, Inc. · $18.89 · Open Payments source 2025-06-30 · Otsuka America Pharmaceutical, Inc. · $19.13 · Open Payments source 2025-07-10 · Otsuka America Pharmaceutical, Inc. · $25.36 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$77.69	4	2025
Source payment records 2025-01-23 · Otsuka America Pharmaceutical, Inc. · $14.31 · Open Payments source 2025-06-02 · Otsuka America Pharmaceutical, Inc. · $18.89 · Open Payments source 2025-06-30 · Otsuka America Pharmaceutical, Inc. · $19.13 · Open Payments source 2025-07-10 · Otsuka America Pharmaceutical, Inc. · $25.36 · Open Payments source
APLENZIN Normalized: aplenzin	Drug	Bausch Health US, LLC	$63.91	3	2025
Source payment records 2025-09-02 · Bausch Health US, LLC · $24.42 · Open Payments source 2025-11-17 · Bausch Health US, LLC · $16.36 · Open Payments source 2025-12-21 · Bausch Health US, LLC · $23.13 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$62.38	3	2025
Source payment records 2025-04-30 · Janssen Pharmaceuticals, Inc · $16.20 · Open Payments source 2025-08-18 · Janssen Pharmaceuticals, Inc · $22.22 · Open Payments source 2025-11-25 · Janssen Pharmaceuticals, Inc · $23.96 · Open Payments source
ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release	Drug	Luye Pharma (USA) Ltd.	$48.33	2	2025
Source payment records 2025-05-13 · Luye Pharma (USA) Ltd. · $20.15 · Open Payments source 2025-10-21 · Luye Pharma (USA) Ltd. · $28.18 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$36.91	2	2025
Source payment records 2025-01-09 · Supernus Pharmaceuticals, Inc. · $16.41 · Open Payments source 2025-10-21 · Supernus Pharmaceuticals, Inc. · $20.50 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$32.42	2	2025
Source payment records 2025-01-03 · Takeda Pharmaceuticals U.S.A., Inc. · $17.58 · Open Payments source 2025-06-26 · Takeda Pharmaceuticals U.S.A., Inc. · $14.84 · Open Payments source
WELLBUTRIN Normalized: wellbutrin	Drug	Bausch Health US, LLC	$24.42	1	2025
Source payment records 2025-09-02 · Bausch Health US, LLC · $24.42 · Open Payments source
ZURZUVAE Normalized: zurzuvae	Drug	Sage Therapeutics, LLC	$20.50	1	2025
Source payment records 2025-10-21 · Sage Therapeutics, LLC · $20.50 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$18.25	1	2025
Source payment records 2025-08-01 · Collegium Pharmaceutical, Inc. · $18.25 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ABILIFY MAINTENA abilify maintena	2025	Abilify Maintena	2024	34 Beneficiary count suppressed	exact normalized	Medicare Part D
ARISTADA aristada	2025	Aristada	2024	16 Beneficiary count suppressed	exact normalized	Medicare Part D
Auvelity auvelity	2025	Auvelity	2024	81 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	78	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	52 Beneficiary count suppressed	exact normalized	Medicare Part D
INVEGA SUSTENNA invega sustenna	2025	Invega Sustenna	2024	79 Beneficiary count suppressed	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	36 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	60 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	31 Beneficiary count suppressed	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	89	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VIIBRYD open payments reported associated product	CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050	Viibryd · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	89	13
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	ARISTADA open payments reported associated product	CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566	Aristada · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	36	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Auvelity open payments reported associated product	CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064	Auvelity · 2024 Exact normalized brand match · 1 Part D row	81	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	78	11
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	78	11
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	79	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	34	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	60	suppressed by CMS
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	52	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	ABILIFY MAINTENA open payments reported associated product	CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721	Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row	34	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	60	suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Clonazepam	Clonazepam	335	40
Duloxetine Hcl	Duloxetine Hcl	312	30
Alprazolam	Alprazolam	306	33
Quetiapine Fumarate	Quetiapine Fumarate	287	32
Trazodone Hcl	Trazodone Hcl	268	44
Buspirone Hcl	Buspirone Hcl	246	30
Lamotrigine	Lamotrigine	226	25
Sertraline Hcl	Sertraline Hcl	191	19
Lorazepam	Lorazepam	175	27
Zolpidem Tartrate	Zolpidem Tartrate	173	24
Escitalopram Oxalate	Escitalopram Oxalate	168	25
Gabapentin	Gabapentin	168	19
Bupropion Xl	Bupropion Hcl	167	16
Fluoxetine Hcl	Fluoxetine Hcl	144	19
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	140	18
Aripiprazole	Aripiprazole	131	21
Mirtazapine	Mirtazapine	120	15
Oxcarbazepine	Oxcarbazepine	114	18
Bupropion Hcl Sr	Bupropion Hcl	100	12
Quetiapine Fumarate Er	Quetiapine Fumarate	95	13
Vilazodone Hcl	Vilazodone Hcl	93	14
Risperidone	Risperidone	89	11
Vraylar	Cariprazine Hcl	89	13
Venlafaxine Hcl Er	Venlafaxine Hcl	86	suppressed
Divalproex Sodium	Divalproex Sodium	82	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	81	suppressed
Invega Sustenna	Paliperidone Palmitate	79	suppressed
Caplyta	Lumateperone Tosylate	78	11
Prazosin Hcl	Prazosin Hcl	78	suppressed
Diazepam	Diazepam	75	13
Eszopiclone	Eszopiclone	74	18
Olanzapine	Olanzapine	69	13
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	63	12
Benztropine Mesylate	Benztropine Mesylate	62	suppressed
Lurasidone Hcl	Lurasidone Hcl	61	suppressed
Rexulti	Brexpiprazole	60	suppressed
Citalopram Hbr	Citalopram Hydrobromide	56	suppressed
Ingrezza	Valbenazine Tosylate	52	suppressed
Zaleplon	Zaleplon	51	14
Quviviq	Daridorexant Hcl	50	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	48	suppressed
Paroxetine Hcl	Paroxetine Hcl	45	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	40	suppressed
Paliperidone Er	Paliperidone	39	suppressed
Temazepam	Temazepam	38	suppressed
Lybalvi	Olanzapine/Samidorphan Malate	36	suppressed
Abilify Maintena	Aripiprazole	34	suppressed
Fetzima	Levomilnacipran Hcl	33	suppressed
Metformin Hcl	Metformin Hcl	33	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	31	suppressed
Trintellix	Vortioxetine Hydrobromide	31	suppressed
Pregabalin	Pregabalin	30	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	29	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	28	suppressed
Dextroamphetamine Sulfate	Dextroamphetamine Sulfate	27	suppressed
Clonidine Hcl	Clonidine Hcl	26	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	26	suppressed
Lithium Carbonate	Lithium Carbonate	26	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	25	suppressed
Divalproex Sodium Er	Divalproex Sodium	22	suppressed
Methylphenidate Er	Methylphenidate Hcl	22	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	20	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	20	suppressed
Dexmethylphenidate Hcl	Dexmethylphenidate Hcl	19	suppressed
Topiramate	Topiramate	18	suppressed
Varenicline Tartrate	Varenicline Tartrate	18	suppressed
Aristada	Aripiprazole Lauroxil	16	suppressed
Lamictal	Lamotrigine	16	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	16	suppressed
Dayvigo	Lemborexant	15	suppressed
Bupropion Hcl	Bupropion Hcl	14	suppressed
Haloperidol	Haloperidol	14	suppressed
Adderall	Dextroamphetamine/Amphetamine	13	suppressed
Atenolol	Atenolol	13	suppressed
Belsomra	Suvorexant	13	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	13	suppressed
Lithium Carbonate Er	Lithium Carbonate	13	suppressed
Trihexyphenidyl Hcl	Trihexyphenidyl Hcl	13	suppressed
Viibryd	Vilazodone Hcl	13	suppressed
Clozapine	Clozapine	12	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	12	suppressed
Carbamazepine	Carbamazepine	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$125,002.99 · 273 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, Jornay PM, LYBALVI, Qelbree, REXULTI, SPRAVATO, TRINTELLIX, UZEDY, VRAYLAR, WELLBUTRIN, ZURZUVAE	14	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Abilify Maintena play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error